Journal of Clinical Oncology
Articles in this Issue
Burden of tracheal, bronchus, and lung cancer in high-income North America: Trends from 1990 to 2021 and death projections to 2050.
e22519 Background: Tracheal, bronchus, and lung cancer (TBL) cancer remain significant public health challenges, particularly in high-income regions of No...
Association between neurological disorders and negative outcomes in head and neck cancer patients during the COVID era: An analysis of health outcomes and economic impact.
e18042 Background: Head and neck cancers (HNC) are associated with significant morbidity and healthcare challenges, often complicated by neurological issu...
Outcomes for adults with KMT2A-r acute myeloid leukemia treated with venetoclax plus azacitidine (Ven/Aza) or intensive chemotherapy (IC): A single-center retrospective study.
e18537 Background: KMT2A-rearranged acute myeloid leukemia (KMT2A-r AML) is known for adverse outcomes due to aggressive disease presentation and high rel...
MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).
TPS7566 Background: Elranatamab (ELRA), a BCMA–CD3 bispecific antibody, induced deep and durable responses with a manageable safety profile as a single ag...
COPEC trial: Early determination of pathological tumor response to neoadjuvant chemotherapy in low/intermediate risk stage II/II rectal cancer—A multicenter, non-inferiority phase III randomized trial.
3535 Background: Multiple large-scale prospective studies have confirmed that neoadjuvant chemotherapy (NCT) alone can achieve optimal distant and local c...
Analysis of data-driven physician engagement and effects on patient recruitment for clinical trial targeting rare gene mutations.
e23286 Background: Advancements in sequencing technology have revolutionized the detection of rare mutations underlying the root cause of genetic diseases...
Cataloging genomic and transcriptomic features of relapsed SCLC.
8107 Background: Relapsed small cell lung cancer (R-SCLC) is characterized by poor outcomes and treatment resistance. The mechanisms driving treatment res...
Expanding role of indocyanine green (ICG) in head and neck cancer surgeries and reconstructive procedures: A preliminary observational study.
e18070 Background: Indocyanine Green (ICG) fluorescence imaging is emerging as a valuable tool in assessing tissue perfusion during head and neck cancer s...
Study protocol: Phase 2 trial of re-treatment with 177Lu-PSMA-617 molecular radiotherapy for metastatic castration resistant prostate cancer (RE-LuPSMA trial).
TPS5110 Background: The phase III VISION trial demonstrated that 177 Lu-PSMA-617 radioligand therapy (RLT) improved overall surviv...
Mechanism of DEPTOR in promoting gemcitabine resistance in pancreatic cancer.
e16375 Background: Pancreatic cancer is a highly aggressive malignancy with an extremely poor prognosis, often referred to as the "king of cancers." Its f...
A multidimensional approach to improve care and outcomes for people with inflammatory breast cancer (IBC).
e13173 Background: Inflammatory Breast Cancer (IBC) is a rare and highly aggressive form of advanced breast cancer. IBC is largely a subjective, clinical...
Evaluation of the combination of regorafenib + avelumab in patients with non-small cell lung cancer without oncogenic addiction: The phase II REGOMUNE study.
8549 Background: Combining anti-angiogenic agents with immune checkpoint inhibitors (ICI) in NSCLC has a strong biological rational. This strategy may enh...
Cerebrospinal fluid proteome during chemotherapy for childhood leukemia: Identifying pathways associated with treatment and system toxicity.
10030 Background: Acute Lymphoblastic Leukemia (ALL) is the most common childhood cancer with a 5-year survival rate > 90%. Survivors treated on contem...
Association of ImPrintTN signature with survival outcomes by race in basal-type triple negative breast cancer (TNBC): FLEX registry analysis.
554 Background: ImPrintTN is a triple negative breast cancer (TNBC) immune classifier signature that has been associated with pathological complete respon...
Clinical activity of EBC-129, a first-in class, anti N256-glycosylated CEACAM5 and CEACAM6 antibody-drug conjugate (ADC), in patients with pancreatic ductal adenocarcinoma (PDAC) in a phase 1 study.
4018 Background: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited treatment options. EBC-1...
A comparative study of the real-world safety and effectiveness of metronomic cyclophosphamide and bevacizumab with or without pembrolizumab for recurrent ovarian cancer.
5590 Background: Metronomic cyclophosphamide and bevacizumab (CB) alone or in combination with pembrolizumab (CBP) are active regimens in heavily pretreat...
Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, phase 3 IRAKLIA study.
7506 Background: IV Isa-Pd is approved to treat RRMM patients (pts) based on the ICARIA-MM study. A Phase 1b study showed safety and efficacy of Isa SC vi...
Activity and toxicity of human mesenchymal stem cells derived from anti-PD1-integrated iPSCs.
e14520 Background: Despite the effectiveness of PD-1 blockade in various cancers, limitations such as poor tumor penetration of aPD-1 antibodies and inabi...
A phase 1a/1b study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of IMGS-001 in patients with relapsed or refractory advanced solid tumors.
TPS2686 Background: IMGS-001 is a fully human, dual specific immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds both PD-L1 and PD-L2, silencing...
Disease response at apheresis and association with long-term outcomes following CAR-T cells for relapsed/refractory multiple myeloma (RRMM).
7518 Background: The two approved BCMA-targeted CAR-T products, cilta-cel and ide-cel, have significant efficacy in RRMM, but are not considered curative....
Severe sarcopenia and symptom burden prior to chemotherapy among older adults (70+) with advanced cancer: A URCC NCORP nationwide study.
12015 Background: Sarcopenia – defined as significant loss of strength, muscle mass and physical function– leads to reduced mobility, increased falls, dif...
Real-world insights into advanced combined small cell lung cancer: Clinical characteristics and therapy.
e20112 Background: Combined small cell lung cancer (C-SCLC) represents a rare subset of small cell lung cancer, with limited clinical data available, part...
Sustained MRD negativity in patients with newly diagnosed multiple myeloma treated with carfilzomib-lenalidomide-dexamethasone with or without isatuximab (phase III IsKia trial).
7502 Background: The phase III IsKia trial assessed the efficacy and safety of isatuximab-carfilzomib-lenalidomide-dexamethasone (IsaKRd) as pre-ASCT indu...
High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIb study.
7047 Background: Relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) has a poor prognosis. Purinostat Mesylate (PM) is a high selective HDAC I/I...
Association of immunotherapy of high-risk neuroblastoma patients with long term infusion of dinutuximab beta with survival over short term infusion: Results from the HR-NBL1/SIOPEN trial.
10000 Background: Dinutuximab beta (DB) delivered as long-term infusion is associated with a lower frequency and magnitude of side effects compared to sho...